Roivant Sciences Ltd. (ROIV) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Roivant Sciences reported revenue of $8.3M, down 71.6% from $29.1M the year before. Net income was -$299.8M (a -3629.2% net margin), or -$0.54 per diluted share. Operating margin was -6235.7%. Operating activities generated -$750.3M of cash, leaving -$758.6M of free cash flow. At fiscal year end, Roivant Sciences held $5.71B in total assets against $416.3M in total liabilities, including $1.42B of cash and equivalents.
Open the full interactive Roivant Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Roivant Sciences Key Stats
| Share Price | $33.35 |
|---|---|
| Market Cap | $24.04B |
| Revenue YoY Growth | -71.6% |
| 52-Week Range | $16.21 – $41.81 |
| Shares Outstanding | 720.8 million (basic, 2027 Q1) |
Roivant Sciences Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Revenue | $55.3M | $61.3M | $124.8M | $29.1M | $8.3M |
| Operating Income | -$1.35B | -$1.18B | $4.24B | -$1.00B | -$515.1M |
| Pre-Tax Income | -$923.7M | -$1.22B | $4.25B | -$681.6M | -$264.6M |
| Income Tax | $369,000 | $5.2M | $22.2M | $48.2M | $133.3M |
| Net Income | -$845.3M | -$1.01B | $4.35B | -$172.0M | -$299.8M |
| Diluted EPS | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
Roivant Sciences Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $1.6M | $2.0M | $2.5M | $1.4M |
| Net Income | -$113.5M | -$265.9M | $303.0M | -$189.8M |
| Diluted EPS | -$0.17 | -$0.38 | $0.44 | -$0.26 |
Roivant Sciences Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.06B | $1.68B | $6.54B | $2.72B | $1.42B |
| Current Assets | $2.15B | $1.80B | $6.73B | $5.00B | $5.17B |
| Total Assets | $2.59B | $2.39B | $7.22B | $5.44B | $5.71B |
| Current Liabilities | $184.4M | $272.4M | $266.8M | $149.4M | $281.2M |
| Total Long-Term Debt | $210.0M | $375.5M | $430.6M | — | — |
| Total Liabilities | $523.7M | $782.0M | $774.0M | $249.7M | $416.3M |
| Shareholders' Equity | $1.66B | $1.16B | $5.97B | $4.69B | $4.53B |
Roivant Sciences Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|
| Cash From Operations | -$677.7M | -$843.4M | -$765.3M | -$839.5M | -$750.3M |
| Cash From Investing | $303.3M | -$44.3M | $5.20B | -$1.77B | -$682.3M |
| Cash From Financing | $306.8M | $499.5M | $419.4M | -$1.22B | $134.2M |
| Free Cash Flow | -$695.2M | -$856.1M | -$766.6M | -$844.0M | -$758.6M |
Figures from Roivant Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Roivant Sciences financials page for every line item.
Roivant Sciences Company Profile
| Ticker | ROIV |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | London |
| Fiscal Year End | March 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001635088 |
Frequently Asked Questions
What was Roivant Sciences' revenue in fiscal 2026?
Roivant Sciences (ROIV) reported revenue of $8.3M for fiscal 2026.
What is Roivant Sciences' annual revenue history?
Roivant Sciences' annual revenue by fiscal year: 2022: $55.3M; 2023: $61.3M; 2024: $124.8M; 2025: $29.1M; 2026: $8.3M.
What was Roivant Sciences' net income in fiscal 2026?
Roivant Sciences reported net income of -$299.8M for fiscal 2026.
What was Roivant Sciences' earnings per share (EPS) in fiscal 2026?
Roivant Sciences' diluted EPS was -$0.54 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Roivant Sciences generate in fiscal 2026?
Roivant Sciences generated -$758.6M of free cash flow in fiscal 2026.
What was Roivant Sciences' revenue last quarter?
In its most recent reported quarter (2027 Q1), Roivant Sciences reported revenue of $1.4M.
How many shares of Roivant Sciences are outstanding?
Roivant Sciences reported a weighted average of 720.8 million basic shares outstanding in 2027 Q1.
What is Roivant Sciences' market cap?
Based on its latest closing price, Roivant Sciences (ROIV) has a market capitalization of about $24.04B.
When does Roivant Sciences' fiscal year end?
Roivant Sciences' fiscal year end, as registered with the SEC, is March 31.
Where is Roivant Sciences headquartered?
Roivant Sciences lists its business address in London in its SEC filings.